Apr 27, 2023 / 09:30PM GMT
Sarah Boyce - Avidity Biosciences, Inc. - President & CEO
Good evening, everybody. For those of us who are joining us in the room here in Boston, thank you so much for attending this event. And for our many colleagues who are listening in over the webcast, welcome.
This evening is incredibly exciting for us at Avidity. This is our seventh in our investor analyst series and the first time we are discussing topline data from one of our programs.
Before we begin, I'd also like to acknowledge, while it's incredibly exciting for us, for the myotonic dystrophy community, both the investigators, the many team members at these sites, and importantly for people who are living with this disease, where there are no approved treatments, and for the longest time there hasn't really been any sign of a potential drug that is active. I'd like to thank all of those members from that community, and in particular, in relation to a readout from a clinical study, particularly a Phase 1/2 study, to acknowledge all of the 38 participants who gave their time to participate in MARINA, as well as their
Avidity Biosciences Inc Investor & Analyst Event Series - Vol. 7: AOC 1001 MARINATM Phase 1/2 Topline Data Call Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers